TTM
$1.98B
YoY change
+15.8%
5Y CAGR
-1.9%
Peak year (2021)
$3.16B
Cumulative EBITDA
$39.39B
EBITDA history chart for Quest Diagnostics (DGX) from 1996 to 2025
Latest: $2.19B
EBITDA growth chart for Quest Diagnostics (DGX) from 1996 to 2025
Latest: +15.8%
EBITDA history table for Quest Diagnostics (DGX) from 1996 to 2025
| 2025 | $2.19B | +15.8% | +$300.00M | ||
| 2024 | $1.89B | +9.4% | +$162.00M | ||
| 2023 | $1.73B | -4.8% | −$88.00M | ||
| 2022 | $1.82B | -42.4% | −$1.34B | ||
| 2021 | $3.16B | +31.0% | +$748.00M | ||
| 2020 | $2.41B | +52.1% | +$826.00M | ||
| 2019 | $1.58B | +12.9% | +$181.00M | ||
| 2018 | $1.40B | -3.4% | −$49.00M | ||
| 2017 | $1.45B | -1.8% | −$26.00M | ||
| 2016 | $1.48B | -4.9% | −$76.00M | ||
| 2015 | $1.55B | +19.2% | +$251.00M | ||
| 2014 | $1.30B | -27.3% | −$489.00M | ||
| 2013 | $1.79B | +17.7% | +$270.00M | ||
| 2012 | $1.52B | +17.0% | +$221.00M | ||
| 2011 | $1.30B | -17.9% | −$283.80M | ||
| 2010 | $1.59B | -2.8% | −$45.40M | ||
| 2009 | $1.63B | +8.7% | +$130.48M | ||
| 2008 | $1.50B | +12.9% | +$171.51M | ||
| 2007 | $1.33B | +0.3% | +$3.81M | ||
| 2006 | $1.33B | +12.0% | +$141.73M | ||
| 2005 | $1.18B | +12.8% | +$134.09M | ||
| 2004 | $1.05B | +10.4% | +$99.22M | ||
| 2003 | $950.36M | +31.3% | +$226.52M | ||
| 2002 | $723.84M | +29.5% | +$164.72M | ||
| 2001 | $559.12M | +23.7% | +$107.00M | ||
| 2000 | $452.11M | +86.2% | +$209.31M | ||
| 1999 | $242.80M | +48.9% | +$79.70M | ||
| 1998 | $163.10M | +7.9% | +$12.00M | ||
| 1997 | $151.10M | -130.1% | +$653.29M | ||
| 1996 | −$502.19M | — | — |
- 2025$2.19B+15.8%
- 2024$1.89B+9.4%
- 2023$1.73B-4.8%
- 2022$1.82B-42.4%
- 2021$3.16B+31.0%
- 2020$2.41B+52.1%
- 2019$1.58B+12.9%
- 2018$1.40B-3.4%
- 2017$1.45B-1.8%
- 2016$1.48B-4.9%
- 2015$1.55B+19.2%
- 2014$1.30B-27.3%
- 2013$1.79B+17.7%
- 2012$1.52B+17.0%
- 2011$1.30B-17.9%
- 2010$1.59B-2.8%
- 2009$1.63B+8.7%
- 2008$1.50B+12.9%
- 2007$1.33B+0.3%
- 2006$1.33B+12.0%
- 2005$1.18B+12.8%
- 2004$1.05B+10.4%
- 2003$950.36M+31.3%
- 2002$723.84M+29.5%
- 2001$559.12M+23.7%
- 2000$452.11M+86.2%
- 1999$242.80M+48.9%
- 1998$163.10M+7.9%
- 1997$151.10M-130.1%
- 1996−$502.19M—
EBITDA values are taken from Quest Diagnostics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Quest Diagnostics (DGX)
According to Quest Diagnostics's latest reported financial statements, the company's current EBITDA (TTM) is $1.98B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Quest Diagnostics (DGX) EBITDA totalled $2.19B – grew 15.8% year-over-year.
Through 2020–2025 (5 years), Quest Diagnostics EBITDA delivered a -1.9% annualised rate; sustaining 2 straight years of year-over-year growth.
Quest Diagnostics EBITDA plunged from $3.16B in 2021 to $2.19B in 2025, a 30.5% drawdown.
The highest annual EBITDA of $3.16B was reported in 2021. The lowest in the available history was −$502.19M in 1996.
Quest Diagnostics EBITDA by Year
Quest Diagnostics EBITDA 2025: $2.19B
Quest Diagnostics EBITDA in 2025 was $2.19B, grew 15.8% from 2024.
Quest Diagnostics EBITDA 2024: $1.89B
2024's EBITDA for Quest Diagnostics came in at $1.89B, grew 9.4% from 2023.
Quest Diagnostics EBITDA 2023: $1.73B
Quest Diagnostics posted EBITDA of $1.73B in 2023, edged down 4.8% below 2022.
Quest Diagnostics EBITDA 2022: $1.82B
In 2022, Quest Diagnostics reported EBITDA of $1.82B, plunged 42.4% below 2021.
Quest Diagnostics EBITDA 2021: $3.16B
Quest Diagnostics EBITDA in 2021 was $3.16B.
See more financial history for Quest Diagnostics (DGX).
Sector peers by EBITDA
Healthcare peers of Quest Diagnostics (DGX), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Quest Diagnostics (DGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation